// App-Quantinova.ai

2842 : A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome–Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Yousif Matloub

Principal Investigators

  • Lia Gore

  • Mignon L. Loh

  • Chin-Hon Pui

  • Michael J. Hanley

  • Vickie Lu

  • E. Jane Leonard

  • Muriel Granier

  • Andrea Biondi

  • Lewis B. Silverman

Medical Centers

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Section of Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado and Children's Hospital Colorado, Aurora, CO

  • University of California San Francisco, UCSF Medical Center-Mission Bay, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Incyte Biosciences International Sàrl,Morges,Schweiz

  • Clinica Pediatrica - Universita di Milano Bicocca, Monza, Italy

  • Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Childrens Hospital, Boston, MA

Locations

  • United States

  • Switzerland

  • Italy

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Acute Leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

Drug/Treatment

  • Ponatinib

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

  • Cohort

Phase

  • I/II

Study Id's

  • NCT04501614

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved